Twist Bioscience Corp (NASDAQ: TWST) stock surged 6.99% in the pre-market trading session on Monday, after the synthetic biology and genomics company reported better-than-expected financial results for the fiscal fourth quarter and full year 2024.
For the fiscal fourth quarter, Twist Bioscience reported a narrower loss of $0.59 per share, beating analyst estimates of a $0.70 loss per share. The company's revenue for the quarter grew 26.53% year-over-year to $84.71 million, surpassing the consensus estimate of $82.20 million.
The strong financial performance was driven by robust demand for Twist's synthetic DNA-based products and services across various industries, including healthcare, industrial chemicals, agriculture, and academic research. The company's proprietary DNA synthesis platform continues to gain traction, positioning Twist Bioscience as a leader in the rapidly growing synthetic biology market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.